Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
JHEP Rep
; 4(11): 100573, 2022 Nov.
Article
in En
| MEDLINE
| ID: mdl-36160754
ALT, alanine transaminase; ASBT, apical sodium-dependent bile acid transporter; ASBTi, ASBT inhibitors; AST, aspartate transaminase; Alagille; Apical sodium-dependent bile acid transporter (ASBT); BDL, bile duct ligation; BSEP; Bile salt pool size; CCl4, carbon tetrachloride; CK7, cytokeratin 7; Cholestasis; FRET, Förster resonance energy transfer; G-OCA, glycine-conjugated OCA; HepG2 cell, hepatocarcinoma cell; IBAT; MDR2, multidrug resistance protein 2; NASH, non-alcoholic steatohepatitis; NGM282, non-tumorigenic fibroblast growth factor 19 analogue; NTCP; NTCP, Na+/taurocholate cotransporting polypeptide; NucleoBAS, nuclear Bile Acid Sensor; OCA, obeticholic acid; PBC, primary biliary cholangitis; PFIC; PentaOH, pentahydroxylated; RT-qPCR, real-time quantitative PCR; Renal excretion; T-OCA, taurine-conjugated OCA; TCA, taurocholic acid; TetraOH, tetrahydroxylated; U2OS, osteosarcoma cell; UHPLC-MS, ultrahigh-performance liquid chromatography mass spectrometry; WT, wild-type
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
JHEP Rep
Year:
2022
Document type:
Article
Affiliation country:
Países Bajos
Country of publication:
Países Bajos